Simultaneous determination of rupatadine and its metabolite desloratadine in human plasma by a sensitive LC-MS/MS method: Application to the pharmacokinetic study in healthy Chinese volunteers

Journal of Pharmaceutical and Biomedical Analysis

Volumn 49, Issue 2, 2009, Pages 347-353

  Wen, Jun ^a,b,c   Hong, Zhanying ^a,b,c   Wu, Yiwen ^a,b,c   Wei, Hua ^a,b,c   Fan, Guorong ^a,b,c   Wu, Yutian ^a,b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI KEY LABORATORY FOR PHARMACEUTICAL METABOLITE RESEARCH   (China)

^c Shanghai Research Centre for Drug Chinese Materia Medica Metabolism   (China)

Author keywords

Desloratadine; Human plasma; LC MS MS; Pharmacokinetics; Rupatadine

Indexed keywords

DESLORATADINE; DIPHENHYDRAMINE; FORMIC ACID; HEXANE; METHANOL; RUPATADINE; TERT BUTYL METHYL ETHER; WATER;

ACCURACY; ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTIPLE REACTION MONITORING; NORMAL HUMAN; PARAMETER; PLASMA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; VALIDITY;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CALIBRATION; CHROMATOGRAPHY, LIQUID; CYPROHEPTADINE; DRUG STABILITY; FEMALE; FORMIC ACIDS; FREEZING; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; METHANOL; MOLECULAR STRUCTURE; PLATELET ACTIVATING FACTOR; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TABLETS; TANDEM MASS SPECTROMETRY; TIME FACTORS; WATER; YOUNG ADULT;

EID: 59049103875     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2008.10.014     Document Type: Article

References (14)

1. Merlos M., Giral M., Balsa D., Ferrando R., Queralt M., Puigdemont A., Garcia-Rafanell J., and Forn J. J. Pharmacol. Exp. Ther. 280 (1997) 114-121
2. Barbanoj M.J., Garcia-Gea C., Antonijoan R., Isquierdo I., Donado E., Perez I., Solans A., and Jane F. Hum. Psychopharmacol. Clin. Exp. 21 (2006) 13-26
3. Guadano E.M., Serra-Batlles J., Meseguer J., Castillo J.A., de Molina M., Valero A., and Picado C. Allergy 59 (2004) 766-771
4. Izquierdo I., Merlos M., and Garcia-Rafanell J. J. Drugs Today 39 (2003) 451-468
5. McClellan K., and Jarvis B. Drugs 61 (2001) 789-796
6. Geha R., and Meltzer E. J. Allergy Clin. Immunol. 107 (2001) 751-762
7. Yumibe N., Huie K., Chen K., Clement R.P., and Cayen M.N. Int. Arch. Allergy Immunol. 107 (1995) 420-429
8. Liu L.H., Qi M.L., Wang P., and Li H.Z. J. Pharm. Biomed. Anal. 34 (2004) 1013-1019
9. Shen J.X., Wang H.P., Tadros S., and Hayes R.N. J. Pharm. Biomed. Anal. 40 (2006) 689-706
10. Yang L.Y., Clement R.P., Kantesaria B., Reyderman L., Beaudry F., Grandmaison C., Donato L.D., Masse R., and Rudewicz P.J. J. Chromatogr. B 792 (2003) 229-240
11. Xu H.R., Li X.N., Chen W.L., and Chu N.N. J. Pharm. Biomed. Anal. 45 (2007) 659-666
12. Tian Y., Zhang J.J., Lin H., Liang J.B., Zhang Z.J., and Chen Y. J. Pharm. Biomed. Anal. 47 (2008) 899-906
13. Solans A., Carbó M., Peña J., Nadal T., Lzquierdo I., and Merlos M. Clin. Ther. 29 (2007) 900-908
14. USFDA (2001), http://www.fda.gov/cder/guidance/4252fnl.htm.